Matches in SemOpenAlex for { <https://semopenalex.org/work/W2243376161> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2243376161 endingPage "84" @default.
- W2243376161 startingPage "273" @default.
- W2243376161 abstract "Infliximab was first approved by the FDA in 1998 as a treatment of moderately-to-severely active Crohn's disease in patients who have an inadequate response to conventional therapies, and fistulizing Crohn's disease. In November 1999 the FDA approved it for use in rheumatoid arthritis with methotrexate, and further expanded this indication in December 2000. It appears to be a promising agent in the treatment of a variety of inflammatory diseases, psoriasis in particular. A MEDLINE search was performed for infliximab in February of 2004, and the 1,116 articles found were reviewed. Approximately 200 articles were identified that contained references to the treatment with infliximab of skin disease, off-label uses, systemic diseases with cutaneous manifestations, and systemic and cutaneous side effects. These articles were reviewed and their contents summarized. Infliximab has been proven in well-controlled trial trials to ameliorate inflammatory bowel disease, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. Anecdotal reports report it useful in treating the cutaneous manifestations and associations of inflammatory bowel disease, Behçet's disease, graft versus host disease, Sjogren's syndrome, refractory sarcoidosis, and a variety of other conditions. Its notable side effects include an increased risk of the induction of infections (e.g., tuberculosis). Infliximab is a very promising medication in the treatment of inflammatory dermatological conditions and should be used in larger scale trials of more diseases." @default.
- W2243376161 created "2016-06-24" @default.
- W2243376161 creator A5026266004 @default.
- W2243376161 date "2004-06-05" @default.
- W2243376161 modified "2023-09-23" @default.
- W2243376161 title "Off-label uses and side effects of infliximab." @default.
- W2243376161 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15176162" @default.
- W2243376161 hasPublicationYear "2004" @default.
- W2243376161 type Work @default.
- W2243376161 sameAs 2243376161 @default.
- W2243376161 citedByCount "6" @default.
- W2243376161 countsByYear W22433761612015 @default.
- W2243376161 countsByYear W22433761612018 @default.
- W2243376161 countsByYear W22433761612021 @default.
- W2243376161 crossrefType "journal-article" @default.
- W2243376161 hasAuthorship W2243376161A5026266004 @default.
- W2243376161 hasConcept C126322002 @default.
- W2243376161 hasConcept C16005928 @default.
- W2243376161 hasConcept C2776260265 @default.
- W2243376161 hasConcept C2777077863 @default.
- W2243376161 hasConcept C2777138892 @default.
- W2243376161 hasConcept C2777402515 @default.
- W2243376161 hasConcept C2777575956 @default.
- W2243376161 hasConcept C2778260677 @default.
- W2243376161 hasConcept C2779134260 @default.
- W2243376161 hasConcept C2780132546 @default.
- W2243376161 hasConcept C2780479503 @default.
- W2243376161 hasConcept C2780564577 @default.
- W2243376161 hasConcept C2781059491 @default.
- W2243376161 hasConcept C2781301800 @default.
- W2243376161 hasConcept C535046627 @default.
- W2243376161 hasConcept C71924100 @default.
- W2243376161 hasConceptScore W2243376161C126322002 @default.
- W2243376161 hasConceptScore W2243376161C16005928 @default.
- W2243376161 hasConceptScore W2243376161C2776260265 @default.
- W2243376161 hasConceptScore W2243376161C2777077863 @default.
- W2243376161 hasConceptScore W2243376161C2777138892 @default.
- W2243376161 hasConceptScore W2243376161C2777402515 @default.
- W2243376161 hasConceptScore W2243376161C2777575956 @default.
- W2243376161 hasConceptScore W2243376161C2778260677 @default.
- W2243376161 hasConceptScore W2243376161C2779134260 @default.
- W2243376161 hasConceptScore W2243376161C2780132546 @default.
- W2243376161 hasConceptScore W2243376161C2780479503 @default.
- W2243376161 hasConceptScore W2243376161C2780564577 @default.
- W2243376161 hasConceptScore W2243376161C2781059491 @default.
- W2243376161 hasConceptScore W2243376161C2781301800 @default.
- W2243376161 hasConceptScore W2243376161C535046627 @default.
- W2243376161 hasConceptScore W2243376161C71924100 @default.
- W2243376161 hasIssue "3" @default.
- W2243376161 hasLocation W22433761611 @default.
- W2243376161 hasOpenAccess W2243376161 @default.
- W2243376161 hasPrimaryLocation W22433761611 @default.
- W2243376161 hasRelatedWork W1147140250 @default.
- W2243376161 hasRelatedWork W1501208090 @default.
- W2243376161 hasRelatedWork W154502539 @default.
- W2243376161 hasRelatedWork W1964314106 @default.
- W2243376161 hasRelatedWork W1975689486 @default.
- W2243376161 hasRelatedWork W2010753554 @default.
- W2243376161 hasRelatedWork W2018572402 @default.
- W2243376161 hasRelatedWork W2051753634 @default.
- W2243376161 hasRelatedWork W2090425592 @default.
- W2243376161 hasRelatedWork W2119798775 @default.
- W2243376161 hasRelatedWork W2153713108 @default.
- W2243376161 hasRelatedWork W2170077422 @default.
- W2243376161 hasRelatedWork W2314288672 @default.
- W2243376161 hasRelatedWork W2413301426 @default.
- W2243376161 hasRelatedWork W2416195819 @default.
- W2243376161 hasRelatedWork W2471802201 @default.
- W2243376161 hasRelatedWork W2755687045 @default.
- W2243376161 hasRelatedWork W3132743342 @default.
- W2243376161 hasRelatedWork W3132939738 @default.
- W2243376161 hasRelatedWork W94611623 @default.
- W2243376161 hasVolume "3" @default.
- W2243376161 isParatext "false" @default.
- W2243376161 isRetracted "false" @default.
- W2243376161 magId "2243376161" @default.
- W2243376161 workType "article" @default.